



CORPORATE PROFILE

Knight Therapeutics Inc., founded in 2014 by Jonathan Ross Goodman (co-founder of Paladin Labs Inc.), is a publicly-traded, specialty pharmaceutical company focused on developing, acquiring, in-licensing, out-licensing, marketing and distributing innovative prescription pharmaceuticals, consumer health products and medical devices in Canada and select international markets. In addition, Knight finances other life sciences companies and invests in life sciences venture capital funds with the goal of securing product distribution rights. Knight has acquired or in-licensed a portfolio of over 20 products that are marketed, under regulatory review or in various stages of development. Knight is headquartered in Montreal, Quebec, Canada and has approximately 40 employees.

FINANCIAL RESULTS

In '000s of CAD except per share amounts

	Nine Months Ended September 30, 2018	Fiscal Year Dec 31, 2017	Fiscal Year Dec 31, 2016
Revenue	8,612	8,634	5,940
Net Income	23,858	17,244	18,560
Cash and marketable securities	775,046	765,033	736,050
Per share ¹	5.43	5.36	5.16
Net Asset Value	1,020,402	991,208	979,718
Per share ¹	7.14	6.94	6.86

¹Based on common shares outstanding as at September 30, 2018

INVESTMENT HIGHLIGHTS

- Proven partner for the Canadian and select international markets
- Demonstrated ability to secure profitable licensing agreements
- Experienced and dynamic management team with proven track record of success
- Financial strength to execute its strategy
- Strategic partnership with Israeli-based Medison

ANALYST COVERAGE

Bloom Burton & Co.

David Martin
dmartin@bloomburton.com

Mackie Research

Andre Uddin
auddin@mackieresearch.com

RBC Dominion Securities

Douglas Miehme
douglas.miehme@research.rbccm.com

Cormack Securities

Tania Gonsalves
tgonsalves@cormack.com

National Bank Financial

Endri Leno
endri.leno@nbc.ca

Raymond James

David Novack
david.novack@raymondjames.com

GMP Securities

Justin Keywood
jkeywood@gmpsecurities.com

Paradigm Capital

Rahul Sarugaser
rsarugaser@paradigmcap.com

TD Securities

Lennox Gibbs
lennox.gibbs@tdsecurities.com

MARKET FACTS

(As at November 8, 2018)

Symbol: **TSX: GUD**

Share Price: **\$8.19**

Shares Outstanding: **142.8 M**

Market Capitalization: **\$1.19 B**

MANAGEMENT TEAM

Jonathan Ross Goodman

CEO

Samira Sakhia

President and CFO

Amal Khouri

VP, Business Development

BOARD OF DIRECTORS

James Gale (Chairman)

Jonathan Ross Goodman

Samira Sakhia

Robert Lande

Sylvie Tandler

Meir Jakobsohn

Nancy Harrison

INVESTOR CONTACT

Knight Therapeutics Inc.
Samira Sakhia, President and CFO
Tel: 514.678.8930
Fax: 514.481.4116
E-mail: info@gudknight.com
Website: www.gudknight.com